A Sphingosine-1-Phosphate Receptor Modulator Attenuated Secondary Brain Injury and Improved Neurological Functions of Mice after ICH

T. Bobinger, T. Bäuerle, L. Seyler, S. v Horsten, S. Schwab, H. B. Huttner, and A. Manaenko

1Department of Neurology of the Friedrich-Alexander-University Erlangen-Nuremberg, Germany
2Department of Radiology of the Friedrich-Alexander-University Erlangen-Nuremberg, Germany
3Department of Experimental Therapy, University Hospital Erlangen, and Preclinical Experimental Animal Center, Friedrich-Alexander-University Erlangen-Nuremberg, Germany

Correspondence should be addressed to A. Manaenko; anatol_manaenko@outlook.com

Received 17 May 2020; Revised 26 July 2020; Accepted 21 August 2020; Published 7 September 2020

Background. Stroke activates the immune system and induces brain infiltration by immune cells, aggravating brain injury. Poststroke immunomodulation via (S1P-)receptor modulation is beneficial; however, the S1P-modulator in clinical use (FTY-720) is unspecific, and undesirable side effects have been reported. Previously, we tested effects of a novel selective S1P-receptor modulator, Siponimod, on ICH-induced brain injury in acute stage of the disease. In the current study, we investigated whether protective effects of Siponimod, evaluated in a short-term study, will protect the brain of ICH animals at long term as well.

Methods. 134 C57BL/6N mice were divided into sham and ICH-operated groups. Collagenase model of ICH was employed. ICH animals were divided into Siponimod treated and nontreated. Dose- and time-dependent effects of Siponimod were investigated. Contraplay between development of brain injury and the number of lymphocytes infiltrating the brain was investigated by forelimb placing, T-Maze test, brain water content calculation, MRI scanning, and immunostaining.

Results. Depending on the therapeutic strategy, Siponimod attenuated the development of brain edema, decreased ICH-induced ventriculomegaly and improved neurological functions of animals after ICH. It was associated with less lymphocytes in the brain of ICH animals.

Conclusion. Siponimod is able to decrease the brain injury and improves neurological functions of animals after ICH.

1. Introduction

The immune system decisively participates on the development of secondary brain injury after stroke. In patients, stroke is associated with an increased number of peripheral inflammation markers (white blood cell (WBC) and peripheral neutrophil count). In animal stroke models, the poststroke brain infiltration by splenocytes significantly contributes to the inflammation and development of secondary brain injury after stroke, resulting in the development of perihematomal brain edema in the acute stage and ventriculomegaly as well as brain atrophy in the chronic stage of disease [1–6].

Previously, beneficial effects of a clinically approved sphingosine-1-phosphate receptor (S1PR) modulator, FTY-720, were demonstrated in preclinical and clinical settings [1, 7, 8]. However, FTY-720 is an unselective modulator of S1PR and side effects are reported [9]. Furthermore, stroke induced immunosuppression, and the infection is a leading cause of death of stroke patients [9]. The long half-life time of FTY-720 might be an explanation for FTY-720-induced lethal infection which is not desirable [10]. Compared to FTY-720, Siponimod has significant lower half-life time and acts only on two out of five receptor isoforms, which are mostly expressed on immune cells [11, 12]. That should be able to avoid the undesirable side effects of the immunomodulation.

In our proceeded paper (https://www.ncbi.nlm.nih.gov/pubmed/31558140), we demonstrated that a second-
generation selective S1P-receptor modulator, Siponimod, dose-dependently attenuated the development of secondary brain injury in acute stage of ICH, resulting in improved neurological functions of ICH animals in a short-time study [13]. Furthermore, we demonstrated that in long term, Siponimod increased the survival rate of treated compared to nontreated animals. However, the long-term effects of Siponimod have not been further evaluated yet [13].

In the current study, we investigated whether beneficial Siponimod-induced short-term effects will also induce a long-term brain protection, resulting in an attenuation of post-ICH ventriculomegaly and brain atrophy as well as neurological dysfunctions.

2. Methods and Materials

All experiments were conducted with the approval of the Government of Unterfranken (approval number 55.2-2532-2-206).

2.1. Intracerebral Hemorrhage Mouse Model. The collagenase model of ICH on mice was used [13]. Mice were anesthetized with ketamine (100 mg/kg) and xylazine (10 mg/kg, intraperitoneal (i.p.) injection), then positioned prone in a stereotactic head frame. Animal core temperature (37 °C) was maintained by a thermostat-controlled warming blanket. The midline scalp was incised from the nasion to the superior nuchal line. The calvarium was exposed. Using a handheld drill device (Fine Scientific Tools, Foster City, CA), a 1 mm burr hole 0.9 mm posterior to the bregma and 2.2 mm to the right of the midline was prepared. A 26 G needle on a Hamilton syringe 3.5 mm was induced into the right deep cortex/basal ganglia at a rate of 1 mm/minute. Collagenase solution (0.075 U in 0.5 μL saline, VII-S; Sigma, St. Louis, MO) was infused at a rate of 0.25 μL/minute using an infusion pump (Stoelting, Wood Dale, IL). After 10 minutes, the needle was withdrawn, the incision was closed, and the mice were allowed to recover. Sham-operated animals received a needle trauma only.

2.2. Treatment and Experimental Groups. 134 C57BL/6N mice (10 weeks, 20-24 g) were obtained from Charles River (Sulzfeld, Germany). Mice were housed in a room with constant temperature (25 °C), humidity control, and a 12/12 h light/dark cycle, free access to food and water.

0.3 and 3.0 (mg/kg of body weight) of Siponimod in 0.5% DMSO (intraperitoneally) were tested. We used either a single 30-minute post-ICH) or multiple (three times: 30 minutes, 24 and 48 hours post-ICH) Siponimod administration.

In the short-time study, animals were neurologically tested 24 and 72 hours after ICH. After the final testing, animals were euthanized and the development of brain edema was investigated by brain water content calculation using the wet/dry method.

In the long-term study, spatial learning was evaluated by a T-Maze test. The progress of brain atrophy and ventriculomegaly was investigated by MRI.

2.3. Evaluation of Brain Edema Development. The development of brain edema was investigated by calculating brain water content [14]. The dry/wet method was used. Briefly, mice were euthanized under deep anesthesia. Brains were removed and divided into five parts: the ipsilateral and contralateral basal ganglia, the ipsilateral and contralateral cortex, and the cerebellum. The cerebellum was used as an internal control for brain water content. Tissue samples were weighed on an electronic analytical balance to the nearest 0.1 mg to obtain the wet weight. The tissue was then dried at 100 °C for 48 h to determine the dry weight. Brain water content (%) was calculated as [(wet weight – dry weight)/ wet weight] × 100.

2.4. Neurobehavioral Function Test. Neurological functions were assessed by forelimb placement (short term, motor functions) and T-Maze (long term, spatial functions) tests [15, 16].

For the limb placement test, the animals were held by their trunk positioned parallel to a table top and slowly moved up and down, allowing the vibrissa to one side of the head to brush along the table surface. Refractory placements of the impaired (left) forelimb were evaluated, and a score was calculated as the number of successful forelimb placements out of 10 consecutive trials [15].

The T-Maze assessed short-term (working) memory [17]. Briefly, mice were placed into the stem of a maze and allowed to explore until one arm was chosen. From the sequence of 10 trials, of left and right arm choices, the rate of spontaneous alternation was calculated (range 0% (no alternation/trial) to 100% (complete, alternations/trial)) [16].

2.5. Tissue Processing and Immunostaining. Under final anesthesia, animals were perfused via intracardiac puncture with ice cold PBS followed by perfusion with 10% PFA. Brain samples were stored in PFA overnight. They were then cryo-preserved with increasing (10, 20, and 30%) concentration of sucrose. Staining was conducted according to vendor recommendation.

Positive cells were quantified in the perihematomal region (N = 3 per group) by an experimenter blinded to the experimental procedure.

2.6. MRI Experiments. MRI was performed on a 7 Tesla scanner dedicated for small animal examinations using a brain coil (ClinScan, Bruker, Ettlingen, Germany). Under isoflurane anesthesia, mice were imaged with the following sequence: 3D mprage (voxel size: 0.117 × 0.117 × 0.25; TR: 2500 ms; TE: 2.82 ms; TA: 22 min). The volumes of ventricles were quantified on MR images using postprocessed Chimera’s segmentation tool (Chimera GmbH, Erlangen, Germany).

2.7. Statistics. Analysis was performed using GraphPad Prism 7.00 software. The data distribution was tested by the D’Agostino and Pearson normality test, and all the data met the criteria of normal distribution. Statistical differences were analyzed with one-way analysis of variance (ANOVA) followed by Dunnett’s multiple comparisons test. Statistical significance was defined as $P < 0.05$. Data are expressed as mean ± standard error of mean.
3. Results

3.1. Siponimod Attenuated the Development of ICH-Induced Brain Edema.
Compared to sham-operated animals, collagenase-induced ICH resulted in significant increase of brain water content in the basal ganglia of all ICH animals evaluated at both 24 and 72 hours after ICH. An increase in brain water content was observed at the ipsilateral cortex as well (Figures 1(a) and 1(b)).

Treatment with both high and low concentrations of Siponimod showed clear tendency for the decrease in post-ICH brain water content at 24 hours. The tendency, however, did not reach statistical significance (Figure 1(a)).

Furthermore, both single and multiple administrations of Siponimod low dose significantly decrease post-ICH brain water content in the basal ganglia at 72 hours. Multiple administration of Siponimod low dose resulted in the reduction of brain water content in the ipsilateral basal ganglia as well. The difference between treated and nontreated animals, however, did not reach statistical significance (Figure 1(b)).

3.2. Siponimod Improved the Neurological Motor Functions of Animals after ICH.
ICH animals demonstrated significant neurological dysfunctions evaluated through the forelimb placing test at 24 and 72 hours after ICH (c,d). Although at 24 hours after ICH Siponimod treatment showed only tendency to decrease post-ICH brain water content, treatment with low concentration of the drug significantly attenuated development of neurological dysfunctions after ICH as evaluated using the forelimb placing test (a and c, respectively). At 72 hours, treatment with low concentration of Siponimod resulted in significant decrease in post-ICH brain water content, whereby the multiple treatment improved neurological functions of ICH animals significantly (b and d, respectively). (*P < 0.05 vs. sham, #P < 0.05 vs. vehicle). Values are expressed as mean ± SD.

Figure 1: Effect of Siponimod on the development of brain edema and neurological dysfunctions after ICH. Compared to sham-operated animals, collagenase-induced ICH resulted in increase in brain water content both at 24 •(a) and 72 (b) hours after insult. Development of brain edema was associated with neurological dysfunctions as evaluated through the forelimb placing test at 24 and 72 hours after ICH (c,d). Although at 24 hours after ICH Siponimod treatment showed only tendency to decrease post-ICH brain water content, treatment with low concentration of the drug significantly attenuated development of neurological dysfunctions after ICH as evaluated using the forelimb placing test (a and c, respectively). At 72 hours, treatment with low concentration of Siponimod resulted in significant decrease in post-ICH brain water content, whereby the multiple treatment improved neurological functions of ICH animals significantly (b and d, respectively). (*P < 0.05 vs. sham, #P < 0.05 vs. vehicle). Values are expressed as mean ± SD.

3.3. Siponimod Attenuated ICH-Induced Brain Injury 10 Days after ICH.
A significant increase in the right ventricle’s size was observed 10 days post-ICH. Furthermore, we
demonstrated that multiple administration of low dose of Siponimod attenuated the development of ICH-induced ventriculomegaly (Figure 2(b)).

3.4. Siponimod Improved the Cognitive Functions of Animals after ICH. For evaluation of cognitive functions of animals, a T-Maze test (a test evaluating impairment of working memory) was used. ICH resulted in significant decrease of spontaneous alteration rate. Multiple treatments with low dose of Siponimod reverse this effect. The difference between sham-operated and ICH animals with multiple treatments with Siponimod was not statistical significant.

3.5. Siponimod Attenuated Brain Infiltration by Systemic Immune Cells. At day 10 post-ICH, Siponimod decreased the number of CD3 but not CD19-positive cells in the perihematomal area of treated animals (Figure 3(b)) compared to nontreated animals (Figure 3(a)).

4. Discussion

In this study, we continued our investigation on the effects of a clinically approved S1P-receptor modulator, Siponimod. We investigated the effects of Siponimod on the development of both short- and long-term secondary brain injuries and neurological deficits after ICH in mice.

Previously, it has been demonstrated that the first-generation S1P-receptor modulator, FTY-720, attenuated post-ICH brain injury in mice [1]. However, FTY-720 is unselective, and its side effects (bradycardia or hypertension) and the occurrence of fatal infection, probably due to a long half-life time, were reported [10, 18]. Siponimod is an agonist of only two isoforms S1P-R1 and S1P-R5 and has a short half-life time [15].

Effects of Siponimod on the ICH-induced brain damage have not been investigated yet. In the first part of the study, we investigated the effects of Siponimod on the development of brain edema. We demonstrated that, in agreement with previous reports, collagenase-induced bleeding results in the disruption of BBB and consequently in the development of posthemorrhagic brain edema. For investigation of brain edema development, we used in this study the “gold standard,” the calculation of brain water content via the “wet/dry” method [14, 15, 19]. At 24 hours after ICH induction, treatment with both low and high concentrations showed a tendency of decreasing hemorrhage-induced brain water content elevation in the ipsilateral basal ganglia. The treatment had no effect on brain water content in the ipsilateral cortex; on the contrary, the difference in brain water content between sham and ICH animals, treated in high concentration, remained statistically significant in this brain region. In agreement with this observation, we were able to
It has been demonstrated previously that while systemic administration of the Siponimod induced lymphopenia, the direct intracerebral administration of the drug had almost no effect on peripheral lymphocyte count [20]. We hypothesize therefore that despite its ability to penetrate BBB, the low concentration of the drug given intraperitoneally affected mostly the peripheral expressed receptors, which control lymphocyte egress from secondary lymphoid organs. There are mounting evidences that stroke-induced increase of the lymphocyte number in circulation results in increased number of lymphocytes infiltrating the brain. This significantly contributes to the rise in inflammation after stroke, and at short term, this results in the development of brain edema [21, 22]. That is in line with our previous observation that the smaller number of cells in blood was accompanied with less brain edema in treated vs. nontreated animals.

It is worth to mention that in addition to its effect on lymphocyte egress, S1P-receptors are involved in the maintenance of the BBB functions, and its signaling regulates endothelial tight junction integrity and is able to protect the brain [23–25]. One can assume that activation of the pathway by natural ligands leads to BBB preservation and brain protection after ICH [26]. The inhibition of the pathway induced by high but not low dose of Siponimod might induce BBB dysfunction and damaged brain cells. The detrimental effects overcome beneficial effects of the inhibition of lymphocyte egress. This hypothesis needs to be further investigated.

Next, we proved whether short-term Siponimod-induced production will also benefit long-term outcomes. The time-dependent effect of ICH on the development of ventriculomegaly after collagenase induced ICH on rats was investigated before [3]. Authors observed the increase in ventricular size as early as three days after ICH with the further increase in ventricular size till day 14 [3]. Also, others observed significant increase in ventricular size after collagenase induced ICH [27, 28]. In agreement with these findings, we demonstrated that ICH resulted in the development of ventriculomegaly. The difference in the ventricular size between nontreated and sham-operated animals was statistically significant. At this part of the project, we only tested the most effective drug concentration and most effective therapeutic strategy, and we demonstrated that multiple administration of low-dose Siponimod resulted in the attenuation of ICH-induced ventriculomegaly.

Pathology of post-ICH ventriculomegaly is not quite clear. ICH-induced inflammation increases permeability of BBB, which allows macromolecules and water to accumulate in an enlarged extracellular space [29]. Furthermore, inflammation induces the cell deaths which leads to the building of cavity around the lesion in the long term [30]. A clinical study demonstrated that there is an association between inflammation and development of hydrocephalus [31]. Even though the pathology of this event needs to be investigated, inflammation seems to play a key role in it as well. It is feasible that attenuation of inflammation and development of brain edema, induced by Siponimod in a short-term study, resulted in long-term brain protection and the decrease in ventricular size.
It has been demonstrated previously that ventriculomegaly is associated with impairment of memory [32, 33]. Inhibition of ventriculomegaly was associated with improvement of memory [34]. We investigated effects of ICH and Siponimod treatment on short-term, working memory by using a short-term (working) memory test, the T-Maze test [17]. Well, in agreement with others, we demonstrated that the significant ICH-induced increase in ventricular size was associated with a significant decrease of spontaneous alteration in the T-Maze. This indicated that in animals with pathological increase of ventricle size, the working memory is impaired. The multiple administration of low-dose Siponimod not only attenuated the development of post-ICH ventriculomegaly but also improved working memory of ICH animals. The difference in the number of spontaneous alterations between sham-operated animals and ICH animals treated with Siponimod was not significant.

Finally, we demonstrated that at day 10, less lymphocytes were present in the brain of animals treated with Siponimod compared with animals which did not receive the treatment. This finding is in agreement with our previous study which demonstrated that the Siponimod treatment significantly decreased the number of circulating lymphocytes in blood of treated compared to nontreated ICH animals [13].

Previously striking increase of inflammatory cytokines and chemokines was demonstrated at 6 and 22 hours after stroke [35]. At these time points, drastic increase in brain water content was also seen [36]. 96 hours after stroke, less inflammation was observed, and at this time point, spleen shrinking, profound (ca. 90%) reduction in the spleen cell number, and apoptosis of spleen cells were detected [37].

The stroke-induced immunosuppression seems to be a result of spleen overactivation. The spleen releases cells in the circulation at the early time point [37]. The cells penetrate the blood brain barrier and contribute to the post-ICH inflammation and development of brain edema. At the time point at which brain edema peaks, the spleen is unable to release more splenocytes in the circulation. This, however, cannot stop the released splenocytes from penetrating BBB and from contributing to post-ICH inflammation.

On the contrary, our treatment intervened at an early time point. We demonstrated that administration of Siponimod as early as 30 minutes after ICH significantly decreases the number of circulating splenocytes which results in the downregulation of the splenocyte number in the brain as well. Due to their decreased number, splenocytes are unable to significantly contribute to post-ICH inflammation. This results in less brain edema. Therefore, the Siponimod-induced immunomodulation at an early time point is beneficial, in contrast to ICH-induced immunosuppression, which can be observed in the delayed time point.

The study has some limitations. Although the pathways underlying S1P modulation have partly been evaluated before [1, 38], the detailed investigation on the molecular level is needed and planned for the next study. Furthermore, the investigation, whether Siponimod would be effective when administered at a later time point and whether Siponimod-induced protection will remain for chronic stage of ICH (one month), will improve our understanding of the Siponimod mode of action.

In summary, a selective, clinically approved, S1P-receptor modulator, Siponimod, is able to attenuate development of brain injury and neurological dysfunction after ICH. This effect was observed both in short- and in long-term studies.

Data Availability

The data used to support the findings of this study are available from the corresponding author upon request.

Disclosure

The sponsor had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation; and decision to submit the manuscript for publication.

Conflicts of Interest

The authors declare no conflict of interest.

Authors’ Contributions

Tobias Bobinger generated the idea of the study and conducted neurological testing. Tobias Bäuerle and Lisa Seyler planned and conducted the MRI study. Stephan von Horsten conducted neurological testing. Tobias Bäuerle and Lisa Seyler conducted the MRI study. Stephan von Horsten generated the idea of the study and participated in the discussion of the results. Stephan Schwab and Hagen B. Huttner participated in the discussion of the project’s clinical relevance. Anatol Manaenko created the project, operated the animals, conducted postmortem investigation, and wrote the manuscript.

Acknowledgments

This study was supported by Novartis (Novartis Pharma GmbH, Grant 36619211).

References

[1] W. B. Rolland, T. Lekic, P. R. Krafft et al., "Fingolimod reduces cerebral lymphocyte infiltration in experimental models of rodent intracerebral hemorrhage," Experimental Neurology, vol. 241, pp. 45–55, 2013.

[2] C. Hua and G. Zhao, "Adult posthaemorrhagic hydrocephalus animal models," Journal of the Neurological Sciences, vol. 379, pp. 39–43, 2017.

[3] R. Li, K. Ma, H. Zhao et al., "Cattle encephalonic glycoside and ignotin reduced white matter injury and prevented post-hemorrhagic hydrocephalus in a rat model of intracerebral hemorrhage," Scientific Reports, vol. 6, no. 1, p. 35923, 2016.

[4] Q. Chen, J. Zhang, J. Guo et al., "Chronic hydrocephalus and perihematoma tissue injury developed in a rat model of intracerebral hemorrhage with ventricular extension," Translational Stroke Research, vol. 6, no. 2, pp. 125–132, 2015.

[5] A. S. Brunswick, B. Y. Hwang, G. Appelboom, R. Y. Hwang, M. A. Piazza, and E. S. Connolly Jr., "Serum biomarkers of spontaneous intracerebral hemorrhage induced secondary
brain injury,” *Journal of the Neurological Sciences*, vol. 321, no. 1-2, pp. 1–10, 2012.

[6] S. Dai, Y. Hua, R. F. Keep, N. Novakovic, Z. Fei, and G. Xi, “Minocycline attenuates brain injury and iron overload after intracerebral hemorrhage in aged female rats,” *Neurobiology of Disease*, vol. 126, pp. 76–84, 2019.

[7] Y. Fu, J. Hao, N. Zhang et al., “Fingolimod for the treatment of intracerebral hemorrhage: a 2-arm proof-of-concept study,” *JAMA Neurology*, vol. 71, no. 9, pp. 1092–1101, 2014.

[8] Y. J. Li, G. Q. Chang, Y. Liu et al., “Fingolimod alters inflammatory mediators and vascular permeability in intracerebral hemorrhage,” *Neuroscience Bulletin*, vol. 31, no. 6, pp. 755–762, 2015.

[9] R. Shim and C. H. Wong, “Ischemia, immunosuppression and infection—tackling the predimonials of post-stroke complications,” *International Journal of Molecular Sciences*, vol. 17, no. 1, p. 64, 2016.

[10] J. A. Cohen, F. Barkhof, G. Comi et al., “Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis,” *The New England Journal of Medicine*, vol. 362, no. 5, pp. 402–415, 2010.

[11] S. Pan, N. S. Gray, W. Gao et al., “Discovery of baf312 (siponimod), a potent and selective s1p receptor modulator,” *ACS Medicinal Chemistry Letters*, vol. 4, no. 3, pp. 333–337, 2013.

[12] K. Selmaj, D. K. B. Li, H.-P. Hartung et al., “Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study,” *The Lancet Neurology*, vol. 12, no. 8, pp. 756–767, 2013.

[13] T. Bobinger, A. Manaenko, P. Burkardt et al., “Siponimod (baf-312) attenuates perihemorrhagic edema and improves survival in experimental intracerebral hemorrhage,” *Stroke*, vol. 50, no. 11, pp. 3246–3254, 2019.

[14] A. Manaenko, P. Yang, D. Nowrangi et al., “Inhibition of stress fiber formation preserves blood-brain barrier after intracerebral hemorrhage in mice,” *Journal of Cerebral Blood Flow and Metabolism*, vol. 38, no. 1, pp. 87–102, 2017.

[15] P. Yang, A. Manaenko, F. Xu et al., “Role of pdgf-d and pdgfr-beta in neuroinflammation in experimental ich mice model,” *Experimental Neurology*, vol. 283, pp. 157–164, 2016.

[16] A. Manaenko, T. Lekic, M. Barnhart, R. Hartman, and J. H. Zhang, “Inhibition of transforming growth factor-beta attenuates brain injury and neurological deficits in a rat model of germin matrix hemorrhage,” *Stroke*, vol. 45, no. 3, pp. 828–834, 2014.

[17] R. N. Hughes, “The value of spontaneous alternation behavior (sab) as a test of retention in pharmacological investigations of memory,” *Neuroscience and Biobehavioral Reviews*, vol. 28, no. 5, pp. 497–505, 2004.

[18] R. M. Fryer, A. Muthukumarana, P. C. Harrison et al., “The clinically-tested s1p receptor agonist, fty720 and baf312, demonstrate subtype-specific bradycardia (S1P1) and hypertension (S1P3) in rat,” *PLoS One*, vol. 7, no. 12, article e52985, 2012.

[19] W. Zhou, M. Marinescu, and R. Veltkamp, “Only very early oxygen therapy attenuates posthemorrhagic edema formation and blood-brain barrier disruption in murine intracerebral hemorrhage,” *Neurocritical Care*, vol. 22, no. 1, pp. 121–132, 2015.

[20] A. Gentile, A. Musella, S. Bullitta et al., “Siponimod (baf312) prevents synaptic neurodegeneration in experimental multiple sclerosis,” *Journal of Neuroinflammation*, vol. 13, no. 1, p. 207, 2016.

[21] W. Li, L. Li, W. Li et al., “Spleen associated immune-response mediates brain-heart interaction after intracerebral hemorrhage,” *Experimental Neurology*, vol. 327, p. 113209, 2020.

[22] S. T. Lee, K. Chu, K. H. Jung et al., “Anti-inflammatory mechanism of intravascular neural stem cell transplantation in hemorrhagic stroke,” *Brain*, vol. 131, no. 3, pp. 616–629, 2008.

[23] K. Yanagida, C. H. Liu, G. Faraco et al., “Size-selective opening of the blood-brain barrier by targeting endothelial sphingosine 1-phosphate receptor 1,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 114, no. 17, pp. 4531–4536, 2017.

[24] S. F. Rodrigues and D. N. Granger, “Blood cells and endothelial barrier function,” *Tissue Barriers*, vol. 3, no. 1-2, article e978720, 2015.

[25] S. Grassi, L. Mauri, S. Prioni et al., “Sphingosine 1-phosphate receptors and metabolic enzymes as druggable targets for brain diseases,” *Frontiers in Pharmacology*, vol. 10, p. 807, 2019.

[26] L. M. Healy, G. K. Sheridan, A. J. Pritchard, A. Rutkowska, F. Mullershausen, and K. K. Dev, “Pathway specific modulation of s1p1 receptor signalling in rat and human astrocytes,” *British Journal of Pharmacology*, vol. 169, no. 5, pp. 1114–1129, 2013.

[27] C. M. Wilkinson, P. S. Brar, C. J. Balay, and F. Colbourne, “Glibenclamide, a sur1-trpm4 antagonist, does not improve outcome after collagenase-induced intracerebral hemorrhage,” *PLoS One*, vol. 14, no. 5, article e0215952, 2019.

[28] C. L. MacLellan, G. Silasi, C. C. Poon et al., “Intracerebral hemorrhage models in rat: comparing collagenase to blood infusion,” *Journal of Cerebral Blood Flow and Metabolism*, vol. 28, pp. 516–525, 2007.

[29] M. C. Papadopoulos, G. T. Manley, S. Krishna, and A. S. Verkman, “Aquaporin-4 facilitates reabsorption of excess fluid in vasogenic brain edema,” *The FASEB Journal*, vol. 18, no. 11, pp. 1291–1293, 2004.

[30] T. Lekic, W. Rolland, R. Hartman et al., “Characterization of the brain injury, neurobehavioral profiles, and histopathology in a rat model of cerebellar hemorrhage,” *Experimental Neurology*, vol. 227, no. 1, pp. 96–103, 2011.

[31] K. W. Wang, C. L. Cho, H. J. Chen et al., “Molecular biomarker of inflammatory response is associated with rebleeding in spontaneous intracerebral hemorrhage,” *European Neurology*, vol. 66, no. 6, pp. 322–327, 2011.

[32] M. T. Williams, A. A. Braun, R. M. Amos-Kroohs et al., “Kainin-induced ventriculomegaly at weaning produces long-term learning, memory, and motor deficits in rats,” *International Journal of Developmental Neuroscience*, vol. 35, no. 1, pp. 7–15, 2014.

[33] H. Sisakonen, S. Oikari, V. P. Korhonen et al., “Diazeapam binding inhibitor overexpression in mice causes hydrocephalus, decreases plasticity in excitatory synapses and impairs hippocampus-dependent learning,” *Molecular and Cellular Neurosciences*, vol. 34, no. 2, pp. 199–208, 2007.

[34] T. Tada, H. Zhan, T. Tanaka, K. Hongo, K. Matsumoto, and T. Nakamura, “Intraventricular administration of hepatocyte growth factor treats mouse communicating hydrocephalus induced by transforming growth factor β1,” *Neurobiology of Disease*, vol. 21, no. 3, pp. 576–586, 2006.

[35] H. Offner, S. Subramanian, S. M. Parker, M. E. Afentoulis, A. A. Vandenbark, and P. D. Hurn, “Experimental stroke
induces massive, rapid activation of the peripheral immune system,” *Journal of Cerebral Blood Flow and Metabolism*, vol. 26, pp. 654–665, 2005.

[36] A. Manaenko, N. Fathali, N. H. Khatibi et al., "Arginine-vasopressin v1a receptor inhibition improves neurologic outcomes following an intracerebral hemorrhagic brain injury,” *Neurochemistry International*, vol. 58, no. 4, pp. 542–548, 2011.

[37] H. Offner, S. Subramanian, S. M. Parker et al., "Splenric atrophy in experimental stroke is accompanied by increased regulatory t cells and circulating macrophages,” *Journal of Immunology*, vol. 176, no. 11, pp. 6523–6531, 2006.

[38] N. Sun, Y. Shen, W. Han et al., "Selective sphingosine-1-phosphate receptor 1 modulation attenuates experimental intracerebral hemorrhage,” *Stroke*, vol. 47, no. 7, pp. 1899–1906, 2016.